Identifying a collaboration partner that can meet the aggressive timelines often associated with highly potent drug candidates is critical. At Lonza Pharma & Biotech, we offer the necessary development, upscaling and manufacturing capabilities under full containment that support API handling to exposure levels to 1ng/m3.

We also offer particle engineering (particle size reduction and spray drying) under isolation as well as specialized dosage forms designed for highly potent, low dose applications. We have more than 20 years’ track record in HPAPI manufacturing and compressed scale-up timelines.

A partner that you can count on for all aspects of your drug program – Lonza.

Contact us 

Contact us: smallmolecules@lonza.com

Webinar on-demand: The journey to a successful Biologics License Application (BLA)
Learn More
Recent webinar in the small molecule field:
Using health-based exposure limits (HBELs) to assess risk
Register Now